Abstract 485P
Background
We demonstrated LDCT lung cancer screening significant improved mortality benefit among Asian never-smokers (NS) compared to ever-smokers (ES). We compared age at diagnosis and characteristics of lung cancer between NS and ES.
Methods
Subgroup analysis were performed from the 14 studies from our previous meta-analysis which included both NS and ES participants and published by April 30, 2021. Our aims were to assess age at lung cancer diagnosis and histology between the 2 groups.
Results
Out of the 14 studies, 4 studies (729 patients/77568 ES, 155 patients/30834 NS) reported age at diagnosis. Eight studies reported histology of lung cancer per patient (5 studies, 207 patients/46,679 ES, 162 cases/35,771 NS) and lung cancer lesion (3 studies, 216 lesions in 192 patients/28898 ES, and 276 lesions in 241 patients/34857NS). Compared to lung cancer in ES, lung cancer in never smokers (LCINS) were diagnosed at younger age though mean year of diagnosis was significantly 1.98 years younger (95% CI -3.38 to – 0.58, I2 0.00%); had a higher proportion of adenocarcinoma (ADC), per patient: 96.58% vs. 69.70% with RR=1.16 (95%CI 0.98 – 1.38, I2 0.00%) and per lesions: 96.81% vs. 68.88% with RR=1.20 (95%CI 1.03 – 1.40, I2 0.00%). Conversely, a lower proportion of squamous cell carcinoma (SqCC), per patient case: 1.37% vs. 16.28% with RR=0.31 (95%CI 0.12 – 0.80, I2 12.41%), and per lung cancer lesions: 0% vs. 14.54% with RR=0.05 (95% CI 0.01 – 0.23, I2 0.00%)). There was a significantly higher RR of ADC over SqCC per patient case: 11.14 (95%CI 2.93 – 42.35, I2 52.10%) among NS vs. 2.49 (95%CI 1.20 – 5.18, I2 69.15%) among ES. The lung cancer lesion ADC/SqCC ratio was also significant per lesion: 73.21 (95%CI 14.83 – 361.54, I20.00%) among NS vs. 3.01 (95%CI 1.98 – 4.57, I2 22.37%) among ES. Two studies reported 3 interval cancers among 8530 ES and none among 9061 NS.
Conclusions
LCINS is predominantly ADC as expected with frequently seen multifocal adenocarcinoma. LCINS was diagnosed on average about 2 years younger in NS than ES suggesting that the age limit to initiate lung cancer screening in NS may be set lower compared to ES.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Nagasaka: Financial Interests, Personal, Advisory Board: AstraZeneca, Caris Life Sciences, Daiichi Sankyo, Novartis, EMD Serono, Janssen, Lilly, Pfizer, Genentech, Mirati, Regeneron, Silverback; Financial Interests, Personal, Invited Speaker: Takeda, Blueprint; Financial Interests, Personal, Other, Travel: AnHeart. E. Shum: Financial Interests, Personal, Advisory Board: AstraZeneca, Genentech, Boehringer-Ingleheim, Janssen, Regeneron; Financial Interests, Institutional, Funding: Delfi Diagnostics. S.I. Ou: Financial Interests, Personal, Invited Speaker: Pfizer, Roche; Financial Interests, Personal, Advisory Board: JNJ/Janssen, Elevation Oncology, AnHeart Therapeutics; Financial Interests, Personal, Ownership Interest: MBrace Therapeutics, BlossomHill Therapeutics; Financial Interests, Institutional, Local PI: Pfizer, Mirati, JNJ/jassen, Merus, Revolution Medicine, Nuvalent. All other authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract